• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 1 day(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 23 day(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 2 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 3 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 4 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 5 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 6 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 7 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    • Mashup Score: 1
      Triplet Delays Further Therapy Versus Doublet in Metastatic HSPC - Neal Shore - 9 month(s) ago

      Neal Shore discusses the ARASENS trial’s post hoc analysis, emphasizing the benefits of triplet therapy in advanced hormone-sensitive prostate cancer. This study adds to the evidence that combining ADT, docetaxel, and darolutamide significantly delays resistant disease development and extends survival. Dr. Shore highlights the shift away from monotherapy ADT towards comprehensive treatment…

      Source: www.urotoday.com
      Categories: General Medicine News, General News
      Tweet Tweets with this article
      • Profile photo of urotoday
        urotoday

        Triplet delays further therapy vs doublet in metastatic #HSPC Neal Shore, MD, FACS @CURCMB joins @CaPsurvivorship @DanaFarber to discuss the #ARASENS trial's post hoc analysis, emphasizing the benefits of triplet therapy in advanced #HSPC. #WathcNow > https://t.co/fxueMqjaIy https://t.co/LWStwqcUKB

    Advertisement

    Advertisement

    MashupMD
    © 2024 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy